The emerging roles and therapeutic potential of exosomes in epithelial ovarian cancer

Li, Xiaoduan; Wang, Xipeng

doi:10.1186/s12943-017-0659-y

Cited by 89 publications

(81 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combining MTA1dE4 expression and AFP levels would be of great value to further stratify patients for determining optimal treatment and follow‐up. Previous studies have demonstrated that MTA1 is detectable in serum of patients with cancers . If plasma levels of MTA1/MTA1dE4 can also be detected during follow‐up after resection for HCC, it would be very useful for timely prediction of HCC recurrence in the future.…”

Section: Discussionmentioning

confidence: 99%

Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus–Associated Hepatocellular Carcinoma

Kao

et al. 2019

Hepatology

View full text Add to dashboard Cite

Overexpression of metastatic tumor antigen 1 (MTA1) was correlated with poor prognosis of hepatitis B virus (HBV)‐associated hepatocellular carcinoma (HBV‐HCC). The aim of this study was to examine the clinical significance of the expression of MTA1 and its exon 4‐excluded form (MTA1dE4), the most abundant spliced variant of MTA1, in patients receiving curative resection for HBV‐HCC. We collected 102 patients with HBV‐HCC and received curative resection retrospectively and examined the expressions level of total MTA1/MTA1dE4 in their paired nontumor and tumor liver tissues by using RT‐qPCR. The association between MTA1/MTA1dE4 expression and various tumor features as well as tumor recurrence was analyzed. During the median follow‐up period of 4 years, 25 patients (24.5%) showed early recurrence (within 12 months postresection) and 42 (54.5%) showed late recurrence. In Kaplan‐Meier analysis, MTA1dE4 overexpression in tumor, but not MTA1, was associated with early recurrence (P = 0.0365), but not late recurrence. In multivariate analysis, only alpha‐fetoprotein (AFP) ≥200 ng/mL (P = 0.006) and large tumor size (P = 0.027) were correlated with early recurrence. In the subgroup of patients with AFP <200 ng/mL, high MTA1dE4, but not total MTA1, expression could help predict early recurrence (P = 0.0195). In vitro, wound healing and invasion assays were performed in HCC cells, and MTA1dE4 was found to exhibit a higher ability in promoting migration and invasion of hepatoma cells than full‐length MTA1. Conclusion: MTA1dE4 expression is correlated with more aggressive tumor characteristics and might serve as a more sensitive marker for early recurrence of HBV‐HCC, especially for low‐AFP patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus–Associated Hepatocellular Carcinoma

Kao

et al. 2019

Hepatology

View full text Add to dashboard Cite

show abstract

“…Typically, cancer cells secrete more exosomes than healthy cells, and the exosomes cargoes differ. Cancer cell-derived exosomes can provide a suitable microenvironment for cancer cell proliferation, drug resistance, angiogenesis, invasion, immune modulation, and premetastatic niche formation (19). In addition, exosomes are suitable for use as a "liquid biopsy" for malignancies, because they are very stable, easy to obtain, and present in almost all body liquids (20,21).…”

Section: Discussionmentioning

confidence: 99%

Serum Exosomal Long Noncoding RNAs ENSG00000258332.1 and LINC00635 for the Diagnosis and Prognosis of Hepatocellular Carcinoma

Chen

Dong

et al. 2018

Cancer Epidemiology, Biomarkers &Amp; Prevention

128

View full text Add to dashboard Cite

Increasing studies suggest that long noncoding RNAs (lncRNAs) are involved in carcinogenesis of human cancers and might be used as diagnostic biomarkers for cancers. A total of 301 participants were recruited in the first part of the study, including a hepatocellular carcinoma (HCC) group ( = 60), liver cirrhosis (LC) group ( = 85), chronic hepatitis B (CHB) group ( = 96), and healthy subjects ( = 60). In the second part, we collected 55 HCC patients, 60 CHB patients, and 60 healthy subjects as an independent cohort to validate the ability of the experiential lncRNAs for identifying HCC from CHB. A commercial kit was used to isolate serum exosomes and total RNA. The relative levels of lnRNAs and mRNA were measured with TaqMan PCR. The results showed that the levels of and in the HCC group were significantly higher than those in the other groups (all < 0.05). A high level in HCC was associated with portal vein tumor emboli, lymph node metastasis, TNM stage, and overall survival (OS; all < 0.05), and a high level was related to lymph node metastasis, TNM stage, and OS (all < 0.05). discriminated HCC from CHB, gaining an area under the ROC curve (AUC) of 0.719 (cutoff value of 1.345); gained an AUC of 0.750 (cutoff value of 1.690). Furthermore, the AUC for the combination of the 2 lncRNAs and serum AFP (cutoff value of 20 μg/L) was 0.894. The abilities of the 2 lncRNAs for identifying HCC from CHB were validated by an independent cohort. The results suggested that the combination of serum exosomal ,, and AFP may be a valuable assay in diagnosis and prognosis of HCC. Our data will shed light on exosomal lncRNAs as biomarkers for HCC. .

show abstract

“…76,77 MiR-222-3p induces polarization of tumour-associated macrophages by the activation of SOCS3/ STAT3 pathway to facilitate tumourigenesis and cancer progression. 78 Additionally, Rab27a supports exosome could modify the tumour microenvironment via advancing recruitment and differentiation of bone marrow-derived neutrophils to cancer cells. 79 Furthermore, a few studies suggest that tumour-derived EVs facilitate cancer progression by attenuating immune and more specific EVs could diminish the cytotoxicity of natural killer cells and T cell in immunoreaction.…”

Section: Modul Ation Of the Tumour Microenvironmentmentioning

confidence: 99%

Extracellular vesicles in urologic malignancies—Implementations for future cancer care

Zhang

Xia

et al. 2019

Cell Proliferation

View full text Add to dashboard Cite

Extracellular vesicles (EVs), a heterogeneous group of vesicles differing in size and shape, cargo content and function, are membrane‐bound and nano‐sized vesicles that could be released by nearly all variations of cells. EVs have gained considerable attention in the past decades for their functions in modulating intercellular signalling and roles as potential pools for the novel diagnostic and prognostic biomarkers, as well as therapeutic targets in several cancers including urological neoplasms. In general, human and animal cells both can release distinct types of EVs, including exosomes, microvesicles, oncosomes and large oncosomes, and apoptotic bodies, while the content of EVs can be divided into proteins, lipids and nucleic acids. However, the lack of standard methods for isolation and detection platforms rein the widespread usage in clinical applications warranted furthermore investigations in the development of reliable, specific and sensitive isolation techniques. Whether and how the EVs work has become pertinent issues. With the aid of high‐throughput proteomics or genomics methods, a fully understanding of contents contained in EVs from urogenital tumours, beyond all doubt, will improve our ability to identify the complex genomic alterations in the process of cancer and, in turn, contribute to detect potential therapeutic target and then provide personalization strategy for patient.

show abstract

The emerging roles and therapeutic potential of exosomes in epithelial ovarian cancer

Cited by 89 publications

References 73 publications

Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus–Associated Hepatocellular Carcinoma

Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus–Associated Hepatocellular Carcinoma

Serum Exosomal Long Noncoding RNAs ENSG00000258332.1 and LINC00635 for the Diagnosis and Prognosis of Hepatocellular Carcinoma

Extracellular vesicles in urologic malignancies—Implementations for future cancer care

Contact Info

Product

Resources

About